UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

Regulation, Reimbursement, and the Long Road of Implementation of Personalized Medicine—A Perspective from the United States

Value in health, 2013-09, Vol.16 (6), p.S27-S31

Frueh, Felix W., PhD

2013

Link zum Volltext

Verfügbarkeit prüfen

The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies

BMC bioinformatics, 2008-08, Vol.9 Suppl 9 (Suppl 9), p.S10-S10, Article S10

2008

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use

Pharmacotherapy, 2008-08, Vol.28 (8), p.992-998

2008

Link zum Volltext

Verfügbarkeit prüfen

Strategic paths for biomarker qualification

Toxicology (Amsterdam), 2008-03, Vol.245 (3), p.219-223

2008

Link zum Volltext

Verfügbarkeit prüfen

Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study

Pharmacotherapy, 2010-08, Vol.30 (8), p.787-796

2010

Link zum Volltext

Verfügbarkeit prüfen

Impact of microarray data quality on genomic data submissions to the FDA

Nature biotechnology, 2006-09, Vol.24 (9), p.1105-1107

Frueh, Felix W

2006

Link zum Volltext

Verfügbarkeit prüfen

Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential

BMC bioinformatics, 2005-07, Vol.6 Suppl 2 (S2), p.S12-S12, Article S12

2005

Link zum Volltext

Verfügbarkeit prüfen

Microarray scanner calibration curves: characteristics and implications

BMC bioinformatics, 2005-07, Vol.6 Suppl 2 (S2), p.S11-S11, Article S11

2005

Link zum Volltext

Verfügbarkeit prüfen

Use of cDNA microarrays to analyze dioxin-induced changes in human liver gene expression

Toxicology letters, 2001-07, Vol.122 (3), p.189-203

2001

Link zum Volltext

Verfügbarkeit prüfen

On rat poison and human medicines: personalizing warfarin therapy

Trends in molecular medicine, 2012-04, Vol.18 (4), p.201-205

Frueh, Felix W

2012

Link zum Volltext

Verfügbarkeit prüfen

Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine

Pharmacogenomics, 2009-07, Vol.10 (7), p.1077-1081

Frueh, Felix W

2009

Link zum Volltext

Verfügbarkeit prüfen

Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer

Clinical cancer research, 2014-03, Vol.20 (6), p.1428-1444

2014

Link zum Volltext

Verfügbarkeit prüfen

Molecular diagnostics clinical utility strategy: a six-part framework

Expert review of molecular diagnostics, 2014-09, Vol.14 (7), p.777-786

2014

Link zum Volltext

Verfügbarkeit prüfen

Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice

Pharmacogenomics, 2010-05, Vol.11 (5), p.657-660

Frueh, Felix W

2010

Link zum Volltext

Verfügbarkeit prüfen

The Use of Denaturing High-Performance Liquid Chromatography (DHPLC) for the Analysis of Genetic Variations: Impact for Diagnostics and Pharmacogenetics

Clinical chemistry and laboratory medicine, 2003-04, Vol.41 (4), p.452-461

2003

Link zum Volltext

Verfügbarkeit prüfen

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information

Journal of personalized medicine, 2013-06, Vol.3 (2), p.111-123

2013

Link zum Volltext

Verfügbarkeit prüfen

Considerations for safety pharmacogenetics in clinical practice

Drug discovery today, 2011-10, Vol.16 (19), p.898-901

Frueh, Felix W.

2011

Link zum Volltext

Verfügbarkeit prüfen

The future of direct-to-consumer clinical genetic tests

Nature reviews. Genetics, 2011-07, Vol.12 (7), p.511

2011

Link zum Volltext

Verfügbarkeit prüfen

Implementing the U.S. FDA guidance on pharmacogenomic data submissions

Environmental and molecular mutagenesis, 2007-06, Vol.48 (5), p.354-358

2007

Link zum Volltext

Verfügbarkeit prüfen

From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community

Pharmacogenomics, 2004-07, Vol.5 (5), p.571-579

2004

Link zum Volltext

Verfügbarkeit prüfen

Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective

Biomarkers in medicine, 2008-06, Vol.2 (3), p.305-311

2008

Link zum Volltext

Verfügbarkeit prüfen

PATIENT KNOWLEDGE OF PHARMACOGENETIC INFORMATION IMPROVES ADHERENCE TO STATIN THERAPY: RESULTS OF THE ADDITIONAL KIF6 RISK OFFERS BETTER ADHERENCE TO STATINS (AKROBATS) TRIAL

Journal of the American College of Cardiology, 2012-03, Vol.59 (13), p.E1848-E1848

2012

Link zum Volltext

Verfügbarkeit prüfen

QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies

Expert review of molecular diagnostics, 2004-11, Vol.4 (6), p.761-777

2004

Link zum Volltext

Verfügbarkeit prüfen

Payer perspectives on pharmacogenomics testing and drug development

Pharmacogenomics, 2009-01, Vol.10 (1), p.149-151

2009

Link zum Volltext

Verfügbarkeit prüfen

Qualification of Biomarkers for Drug Development in Organ Transplantation

American journal of transplantation, 2008-02, Vol.8 (2), p.267-270

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(47)
Buchkapitel
(1)

Sprache

Englisch
(48)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Life Sciences & Biomedicine
(32)
Humans
(19)
United States
(12)
Pharmacology & Pharmacy
(11)
Biological And Medical Sciences
(10)
Medical Sciences
(9)
United States Food And Drug Administration
(9)
Pharmacogenomics
(8)
Animals
(7)
Biomarkers
(7)
Pharmacogenetics
(7)
Biochemistry & Molecular Biology
(6)
Toxicology
(6)
Biotechnology & Applied Microbiology
(5)
Decision Making
(5)
Drug Development
(5)
Pharmacogenetics - Methods
(5)
Pharmacogenetics - Standards
(5)
Personalized Medicine
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Regulation, Reimbursement, and the Long Road of Implementation of Personalized Medicine—A Perspective from the United States

The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies

Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use

Strategic paths for biomarker qualification

Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study

Impact of microarray data quality on genomic data submissions to the FDA

Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential

Microarray scanner calibration curves: characteristics and implications

Use of cDNA microarrays to analyze dioxin-induced changes in human liver gene expression

On rat poison and human medicines: personalizing warfarin therapy

Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine

Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer

Molecular diagnostics clinical utility strategy: a six-part framework

Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice

The Use of Denaturing High-Performance Liquid Chromatography (DHPLC) for the Analysis of Genetic Variations: Impact for Diagnostics and Pharmacogenetics

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information

Considerations for safety pharmacogenetics in clinical practice

The future of direct-to-consumer clinical genetic tests

Implementing the U.S. FDA guidance on pharmacogenomic data submissions

From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community

Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective

PATIENT KNOWLEDGE OF PHARMACOGENETIC INFORMATION IMPROVES ADHERENCE TO STATIN THERAPY: RESULTS OF THE ADDITIONAL KIF6 RISK OFFERS BETTER ADHERENCE TO STATINS (AKROBATS) TRIAL

QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies

Payer perspectives on pharmacogenomics testing and drug development

Qualification of Biomarkers for Drug Development in Organ Transplantation

Suchergebnisse filtern